🔗 Share this article

While America proceeds with historic changes to its immunization schedules, an unexpected name has surfaced in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on COVID-19 vaccines in the pandemic and has zeroed in on possible fatalities after Covid immunization in her short position at the FDA.

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities planned to announce sweeping changes to the childhood vaccination calendar in December, aligning the US with the Danish immunization schedule, sources say – a significant shift that would put the US at odds with many the international standard with little proof for improved outcomes. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to speak at the gathering. She was just designated acting director of the FDA’s CDER, the fifth individual to run the office this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine centers as Høeg and Prasad solidify control at the FDA – and it signals a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US so as to align more similar to Denmark, a nation with universal health coverage and a population about the population of the state of Wisconsin.

So far public appearances, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no apparent background in drug development, regulation or management, which has been customary for past heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for running the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of CBER would “grasp laws and regulations and the research of medication creation”, commented Janet Woodcock. “Clearly, she doesn’t have the type of experience that former directors who headed the center have had.”

CDER has an vast workload at the agency, Woodcock pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars program, over-the-counter program and more, and all of those have to be looked after,” she noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major management aspect to the job, which oversees in excess of 5,000 staff members. “It is a huge management job, if you execute it properly,” Woodcock concluded.

Response and Controversial Policies

In response to inquiries about Høeg’s credentials and whether this appointment signifies more teamwork among regulatory chiefs on immunizations, a representative stated that the “concerns are based on flawed premises”.

“Her resume matches the responsibilities of her position,” the spokesperson explained, noting the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Dr. Høeg inherits the agency head's controversial priority voucher program, a contentious one-day therapy clearance system that allegedly worried her preceding directors. “By what process are these medications being chosen for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards laxer regulations of all drugs, with the exception of shots.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if concerning, track record, some experts said. She published a study using unverified public submissions to determine the incidence of heart inflammation after COVID-19 vaccination. She consulted for the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current administration encompassed revising guidelines for novel immunizations and halting “unnecessary” immunizations, she remarked post-election on a online show. At the agency, Dr. Høeg has allegedly proposed barring young men from getting COVID-19 vaccines.

“She’s an complete true believer who commences with her beliefs and tailors the evidence to fit the evidence in a extremely deceptive, dishonest fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|